An outsourced animal health development team for human life sciences companies

A human therapeutic asset can have compelling animal health potential and still be too early for an animal health transaction. Common gaps include limited target-species proof of concept, no veterinary product strategy, an undefined regulatory pathway, incomplete animal-health-specific CMC or formulation work, no commercialization plan, and an uncertain market valuation.

Akretiv acts as an outsourced animal health development team. We evaluate the existing human data package and veterinary opportunity; secure an option or other defined animal health rights; establish a target product profile; identify the studies, regulatory work and commercial evidence required for the next value inflection point; build the program budget; and coordinate execution through selected animal health specialists, CROs, CDMOs and strategic relationships.

The human life sciences partner contributes the knowledge and development foundation already created for the asset, which may include toxicology, CMC, manufacturing, formulation and human clinical information. The partner may elect to co-fund the program. When additional capital is needed, Akretiv may organize a dedicated SPV and bring in animal health investors, allowing the veterinary program to advance without becoming an operational or financial distraction from the partner's core human pipeline.

Akretiv manages the program toward a strategic animal health transaction. Depending on the asset and market interest, that transaction may be an early program sale, a license, a co-development agreement, a distribution arrangement or a later transaction near or after regulatory approval. Economic rights, ownership, data access, manufacturing and future participation are defined in the negotiated agreement for each program.

This model can create a new animal health value pathway for the human partner while giving an animal health strategic partner access to a more advanced, better characterized and more commercially prepared opportunity.

Have a human life sciences asset with potential in animal health? Contact Akretiv for a confidential initial discussion about veterinary fit, development gaps and possible partnership structures.

Why work with Akretiv?

• Akretiv provides a dedicated team with deep animal health expertise

• Akretiv has relationships with animal health pharmaceutical companies (potential distribution deals, strategic exits)

• Efficient, milestone-driven development supported by program-appropriate financing structures